Ameriprise Financial Inc. Boosts Stock Holdings in Celcuity Inc. (NASDAQ:CELC)

Ameriprise Financial Inc. grew its position in Celcuity Inc. (NASDAQ:CELC - Free Report) by 45.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 447,171 shares of the company's stock after buying an additional 140,642 shares during the period. Ameriprise Financial Inc. owned 1.20% of Celcuity worth $5,853,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CELC. Candriam S.C.A. bought a new stake in shares of Celcuity in the 4th quarter valued at about $3,450,000. Artisan Partners Limited Partnership boosted its holdings in shares of Celcuity by 18.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 491,507 shares of the company's stock valued at $6,434,000 after buying an additional 75,830 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Celcuity by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 692,372 shares of the company's stock valued at $9,065,000 after buying an additional 62,003 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Celcuity by 16.4% in the 4th quarter. Northern Trust Corp now owns 300,076 shares of the company's stock valued at $3,928,000 after buying an additional 42,186 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Celcuity by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock valued at $21,624,000 after buying an additional 24,429 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Performance

Shares of Celcuity stock traded up $0.32 during midday trading on Thursday, hitting $10.82. The company had a trading volume of 94,473 shares, compared to its average volume of 298,735. The stock has a market cap of $409.71 million, a price-to-earnings ratio of -4.15 and a beta of 0.56. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $10.19 and a 200 day simple moving average of $11.39. Celcuity Inc. has a 12-month low of $7.58 and a 12-month high of $19.77.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. As a group, analysts predict that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CELC. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a research report on Monday, May 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a research report on Thursday, May 15th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $30.80.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.